Founded in 2006 and headquartered in Daejeon, South Korea, LigaChem Biosciences (LCB) is a clinical-stage biopharmaceutical company dedicated to developing next-generation cancer therapies — led by ADC innovation and expanding into new modalities to address unmet patient needs.

Our proprietary ADC platform ConjuAll™ integrates site-specific conjugation, a patented β-Glucuronide Linker, and novel payload technology to overcome the core limitations of conventional ADCs: linker instability, insufficient tumor selectivity, and payload resistance. 

Clinically validated across 5 ADCs in clinical stage and honored at the World ADC Awards for multiple consecutive years, ConjuAll™ is one of the most proven ADC platforms in the industry. To date, we have closed 15 ADC-related deals totaling over $8.7B in disclosed value — with partners across the U.S., Europe, and Asia.

Powered by open innovation, we combine our proprietary technologies with the world's best expertise — creating scientific synergy that accelerates therapies from discovery to patients, faster.

For additional information, please visit www.ligachembio.com

LigaChem Biosciences

Org chart

Teams

Offices

LigaChem Biosciences

Org chart

Teams

Offices

Related companies